Alumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54% PASI 100 At Week 48; NDA On Track For 4Q 2026

– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis

– Patients switching from placebo or apremilast achieved rapid responses, comparable to those on continuous treatment at Week 48 

– On track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026